Research graph
References from Physicochemical Characterization, Molecular Docking, and In Vitro Dissolution of Glimepiride–Captisol Inclusion Complexes. Local targets link to admitted publications; unresolved targets remain external evidence.
The Role of Glimepiride in the Effective Management of Type 2 Diabetes
10.1016/j.jdiacomp.2004.07.001 · 2004 · External reference
Solubility Enhancement Strategies for Poorly Water-Soluble Drugs in Solid Dispersions: A Review
2016 · External reference
Pharmaceutical Particle Technologies: An Approach to Improve Drug Solubility, Dissolution and Bioavailability
10.1016/j.ajps.2014.05.005 · 2014 · External reference
Cyclodextrin-Based Pharmaceutics: Past, Present and Future
10.1038/nrd1576 · 2004 · External reference
Physicochemical Characterization and Dissolution of Norfloxacin/Cyclodextrin Inclusion Compounds and PEG Solid Dispersions
10.1016/0378-5173(95)00039-l · 1995 · External reference
Similar Modes of Inclusion in Complexes of β-Cyclodextrin with Sulfonylurea Hypoglycemic Drugs
10.1039/b908128c · 2010 · External reference
Effectiveness of Mechanochemical Treatment with Cyclodextrins on Increasing Solubility of Glimepiride
10.1691/ph.2009.9045 · 2009 · External reference
Formulation and Biological Evaluation of Glimepiride–Cyclodextrin–Polymer Systems
10.1016/j.ijpharm.2005.11.024 · 2006 · External reference
Inclusion Complexation of Glimepiride in Dimethyl-β-Cyclodextrin
2007 · External reference
Implication of Inclusion Complexation of Glimepiride in Cyclodextrin–Polymer Systems on Its Dissolution, Stability and Therapeutic Efficacy
10.1016/j.ijpharm.2006.04.002 · 2006 · External reference
Combined Use of Cyclodextrins and Hydroxypropylmethylcellulose Stearoxy Ether (Sangelose®) for the Preparation of Orally Disintegrating Tablets of Type-2 Antidiabetes Agent Glimepiride
10.1007/s10847-014-0386-6 · 2014 · External reference
Comparative Interaction of 2-Hydroxypropyl-β-Cyclodextrin and Sulfobutylether-β-Cyclodextrin with Itraconazole: Phase-Solubility Behavior and Stabilization of Supersaturated Drug Solutions
10.1016/j.ejps.2008.02.007 · 2008 · External reference
Improved Aqueous Solubility of Crystalline Astaxanthin (3, 3′-dihydroxy-β, Β-carotene-4, 4′-dione) by Captisol®(Sulfobutyl Ether Β-cyclodextrin)
10.1002/jps.10359 · 2003 · External reference
Preclinical Studies of a Kidney Safe Iodinated Contrast Agent
10.1111/jon.12356 · 2016 · External reference
Physicochemical Characterization and in Vitro Dissolution Performance of Ibuprofen-Captisol®(Sulfobutylether Sodium Salt of β-CD) Inclusion Complexes
10.1016/j.molliq.2018.04.007 · 2018 · External reference
Solution Stability of Captisol-Stabilized Melphalan (Evomela) versus Propylene Glycol-Based Melphalan Hydrochloride Injection
10.1080/10837450.2016.1265557 · 2018 · External reference
Influence of Sulfobutyl Ether β-Cyclodextrin (Captisol®) on the Dissolution Properties of a Poorly Soluble Drug from Extrudates Prepared by Hot-Melt Extrusion
10.1016/j.ijpharm.2007.08.038 · 2008 · External reference
The Use of Captisol (SBE7-β-CD) in Oral Solubility-Enabling Formulations: Comparison to HPβCD and the Solubility–Permeability Interplay
10.1016/j.ejps.2015.05.024 · 2015 · External reference
Structural Characterization of N-Protonated Amides: Regioselective N-Activation of Medium-Bridged Twisted Lactams
10.1021/ja101690u · 2010 · External reference
Effect of Acid, Base and Time on Different Brands of Glimepiride
2014 · External reference
Temperature, Stability, and the Hydrophobic Interaction
10.1016/s0006-3495(97)78324-3 · 1997 · External reference
A Phase Solubility Technique
1965 · External reference
Cyclodextrins and Ternary Complexes: Technology to Improve Solubility of Poorly Soluble Drugs
10.1590/s1984-82502011000400003 · 2011 · External reference
Influence of the Preparation Method on the Physicochemical Properties of Ketoprofen–Cyclodextrin Binary Systems
10.1016/s0378-5173(98)00390-1 · 1999 · External reference
Can Entropy and “Order” Increase Together?
10.1016/0375-9601(84)90934-4 · 1984 · External reference
Role of Cyclodextrins in Improving Oral Drug Delivery
10.2165/00137696-200402040-00006 · 2004 · External reference
Analysis of Steady State and Non-Steady State Corneal Permeation of Diclofenac
10.1039/c6ra03604j · 2016 · External reference
G_mmpbsa A GROMACS Tool for High-Throughput MM-PBSA Calculations
10.1021/ci500020m · 2014 · External reference
A Characterization Study of Resveratrol/Sulfobutyl Ether-β-Cyclodextrin Inclusion Complex and in Vitro Anticancer Activity
10.1016/j.colsurfb.2013.11.025 · 2014 · External reference
Novel Pimozide-β-Cyclodextrin-Polyvinylpyrrolidone Inclusion Complexes for Tourette Syndrome Treatment
10.1016/j.molliq.2015.12.054 · 2016 · External reference
Enhanced Oral Bioavailability of Acyclovir by Inclusion Complex Using Hydroxypropyl-β-Cyclodextrin
10.3109/10717544.2013.853213 · 2014 · External reference
Inclusion Complexes of Tadalafil with Natural and Chemically Modified β-Cyclodextrins I: Preparation and in-Vitro Evaluation
10.1016/j.ejpb.2008.06.024 · 2008 · External reference
Surface Solid Dispersion of Glimepiride for Enhancement of Dissolution Rate
2009 · External reference
Ternary Complexation of Carvedilol, β-Cyclodextrin and Citric Acid for Mouth-Dissolving Tablet Formulation
10.2478/v10007-009-0001-3 · 2009 · External reference
Cyclodextrins as Functional Excipients: Methods to Enhance Complexation Efficiency
10.1002/jps.23077 · 2012 · External reference
GROMACS: A Message-Passing Parallel Molecular Dynamics Implementation
10.1016/0010-4655(95)00042-e · 1995 · External reference
GROMACS 3.0: A Package for Molecular Simulation and Trajectory Analysis
10.1007/s008940100045 · 2001 · External reference
Comparison of three molecular simulation approaches for cyclodextrin-ibuprofen complexation
10.1155/2015/193049 · 2015 · External reference
Preperation And Characterization Of Β-Cyclodextrin Inclusion Complexes Oral Tablets Containing Poorly Water Soluble Glimipiride Using Freeze Drying Method
10.14499/indonesianjpharm26iss2pp71 · 2015 · External reference
What Is a Suitable Dissolution Method for Drug Nanoparticles?
10.1007/s11095-008-9560-0 · 2008 · External reference
